1. Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A Five-Year Experience
- Author
-
Yi Zhang, Hongyu Ren, Yang He, Jingang An, and Shuo Chen
- Subjects
Related factors ,Multivariate statistics ,medicine.medical_specialty ,Bone Density Conservation Agents ,Diphosphonates ,business.industry ,Retrospective cohort study ,Logistic regression ,medicine.disease ,Zoledronic Acid ,Confidence interval ,Zoledronic acid ,Jaw ,Otorhinolaryngology ,Internal medicine ,Humans ,Medicine ,Bisphosphonate-Associated Osteonecrosis of the Jaw ,Surgery ,Oral Surgery ,Risk factor ,business ,Osteonecrosis of the jaw ,Retrospective Studies ,medicine.drug - Abstract
Purpose The treatment of medication-related osteonecrosis of the jaw (MRONJ) is greatly challenging for surgeons. In this study, we reviewed patients with MRONJ treated in our hospital in the past 5 years and explored the risk factors of recurrence. Methods A retrospective cohort study was conducted to review the patients with MRONJ from January 1, 2016 to December 31, 2020. All patients received a monthly intravenous application of zoledronic acid. The primary outcome variable was the treatment outcome during follow-up. The predictor variables were local and systemic factors related to the treatment outcome. Multivariate logistic regression analysis was performed to identify the risk factors of recurrence after MRONJ treatment. Results A total of 58 patients (62 sites) were included in this study. In multivariate regression analysis, the risk factor associated with recurrence after MRONJ treatment was the duration of medication of more than 18 months (odds ratio = 7.346; 95% confidence interval: 1.461-36.946; P = .016). Conclusions Using zoledronic acid over 18 months may increase the risk of recurrence in MRONJ patients.
- Published
- 2021